Characterizing Deep Quality-of-Life Response in the TRuE-V1/TRuE-V2 Studies of Ruxolitinib Cream in Nonsegmental Vitiligo

Main Article Content

Seemal R. Desai
University of Texas Southwestern Medical Center, Dallas, Texas, USA; Innovative Dermatology, Plano, Texas, USA

Thierry Passeron
Centre Hospitalier Universitaire de Nice, Université Côte d’Azur, Nice, France; INSERM U1065, C3M, Université Côte d’Azur, Nice, France

Pearl Grimes
The Vitiligo and Pigmentation Institute of Southern California, Los Angeles, California, USA

Khaled Ezzedine
Henri Mondor University Hospital and Université Paris-Est Créteil, Créteil, France

John E. Harris
University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA

Amy J. McMichael
Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA

Dan Sturm
Incyte Corporation, Wilmington, Delaware, USA

Xavier Diaz
Incyte Corporation, Wilmington, Delaware, USA

Haobo Ren
Incyte Corporation, Wilmington, Delaware, USA

David Rosmarin
Indiana University School of Medicine, Indianapolis, Indiana, USA

Keywords

Vitiligo, Quality of life, ruxolitinib

Abstract

N/A

References

1. Bibeau K, et al. JAMA Dermatol. 2023;159(10):1124-1128.

2. Rodrigues M, et al. J Am Acad Dermatol. 2017;77(1):1-13.

3. Rosmarin D, et al. N Engl J Med. 2022;387(16):1445-1455.

4. Kitchen H, et al. Dermatol Ther (Heidelb). 2022;12(7):1623-1637.

5. Finlay AY, Khan GK. Clin Exp Dermatol. 1994;19(3):210-216.

Article Sidebar

PDF
Published
2026-03-10
DOI: https://doi.org/10.25251/bpnxm492

Article Details

How to Cite
1.
Characterizing Deep Quality-of-Life Response in the TRuE-V1/TRuE-V2 Studies of Ruxolitinib Cream in Nonsegmental Vitiligo. J of Skin. 2026;10(2):s752. doi:10.25251/bpnxm492
Issue
Vol. 10 No. 2 (2026): March 2026 Issue
Section
Vitiligo
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 1 2 3 4 5 6 > >>